Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Sees Biomarker-Guided Discovery As Key To Unlocking Tumor Microenvironment

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

For Roche, PD-L1 is just the first target to emerge from its big investment in understanding the immunosuppressive tumor microenvironment. The company’s research operations use biomarkers to guide discovery and increasingly important early development and combination strategies – potentially a more fruitful use of biomarker strategies than parallel development of companion diagnostics and therapeutics.

You may also be interested in...



Roche Pushes The Boundaries Of Cancer Immunotherapy

Roche is betting that its tumor immunophenotype research can guide combination therapy that will alter the tumor microenvironment, making tumor types than have been resistant to PD-1/L1 inhibitors sensitive to immunotherapy.

A Quick Primer On Roche's Immuno-Oncology Assets

Roche's broad cancer immunotherapy pipeline features a dozen novel agents, including the first candidates from new therapeutic platforms for bispecific antibodies and personalized cancer vaccines.

Keytruda Approval Opens New Routes For Immuno-Oncology

Merck's PD-1 inhibitor holds the first cancer indication based on biomarkers rather than tumor location. The most significant market will be colorectal cancer, but Bristol-Myers Squibb's Opdivo is pending for the same subgroup and Roche's Tecentriq could eventually gain a broader approval.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS005746

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel